General MedicationsORALGeneric

LAMIVUDINE; STAVUDINE

Standard Dose

150MG; 40MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: None (Tentative Approval)

Summary

Approval overview LAMIVUDINE; STAVUDINE is listed in Drugs@FDA under application 022085 (NDA).

Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; STAVUDINE Form and strength TABLET; ORAL - 150MG; 40MG Sponsor MATRIX LABS Submission history Latest submission status date: 2007-11-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE; STAVUDINE is listed in Drugs@FDA under application 022085 (NDA). Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; STAVUDINE Form and strength TABLET; ORAL - 150MG; 40MG Sponsor MATRIX LABS Submission history Latest submission status date: 2007-11-02 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.